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Huntington’s disease (HD) is a devastating neurodegenerative 
condition caused by a triplet repeat expansion of the 
huntingtin gene (1). Although rare it is amongst the most 
frequent autosomal dominant causes of dementia, frequently 
affecting individuals in the most productive decades of 
their lives. Clinically, it is characterized by a classic triad 
of fluctuating neuropsychiatric symptoms, and progressive 
movement and cognitive disorders, accompanied by other 
symptoms such as weight loss and sleep impairment. It is 
severely debilitating, has a huge impact on quality of life and 
is fatal, with a median survival after motor onset of around a 
quarter of a century (2).
The culprit genetic defect was first assigned to 
chromosome 4 in 1983 (3) and sequenced in 1993 (4). 
Whilst great hope had been placed on this discovery, nearly 
three decades later there is still no cure or any intervention 
that delays or stops disease progression (5). Nevertheless, 
several promising compounds are currently active in the 
drug development pipeline (6).
With regards to symptom management the therapeutic 
armamentarium is broad, although few interventions are 
supported by high quality evidence (7). As an example, 
for the hyperkinetic movement disorder (i.e., chorea) 
characteristic of HD, there are currently two FDA-approved 
medications—tetrabenazine and deutetrabenazine—
although unclarity still exists about how dissimilar their 
efficacy and safety profiles are (8,9).
H D  i s  a  p r o m i s i n g  d i s e a s e  m o d e l  t o  s t u d y 
neurodegeneration, due to several characteristics, including: 
a precise pathogenic agent (4), a natural history that 
comprises a long presymptomatic phase (10,11) followed 
by an extended diseased survival (12), a broad symptomatic 
spectrum including most of the clinical features present 
on neurodegenerative diseases (motor, behavioural and 
cognitive) (1), well-validated assessment tools (13-16), 
pioneering imaging and biofluid biomarkers (10,17), and 
well-organized research and patient networks (18). These 
factors have encouraged drug developers to invest in HD as 
shown by the proportionately high number of clinical trials 
conducted in this rare disease population. Unfortunately, 
the success rate of the development pipeline underperforms 
when comparing with other disorders (5).
Genetic interventions are only now coming to 
age due to recent breakthroughs in DNA and RNA 
manipulation techniques, and optimization of drug stability, 
immunogenicity and delivery. There is optimism that 
these new tools may help change the fate of diseases like 
Huntington’s. The ideal drug development program needs 
to happen with minimal human and financial burden and 
maximal efficiency. This includes informative preclinical 
data and early phase trial results, but also early “go/no go” 
decision timings and criteria.
Pridopidine is an interesting molecule from the 
pharmacological perspective (Figure 1). Acting on the 
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dopaminergic system—which is primarily involved in 
the genesis of the disease phenotype—it is classified 
as a modulator as it can have both an agonistic and 
antagonistic effects through a state-dependent effect on 
dopamine receptors. When there is overactivity it acts as an 
antagonist, under underactivity conditions as an agonist, and 
has little to no influence under physiological circumstances. 
In addition, it also seems to interact with N-Methyl-D-
aspartate (NMDA) and sigma-1 receptors.
Thus far pridopidine has been tested in four successive 
randomized controlled trials (RCTs) in HD, enrolling a 
grand total of over 1,000 participants (Table 1) (19,20,22,24). 
Unfortunately, in all of them the primary outcome was 
not met.
At first, a small RCT tested 50 mg of pridopidine a day 
against placebo in 58 people with manifest HD, recruited 
from 6 centres in Sweden and Norway. The trial followed 
participants for 4 weeks and was not able to show an effect 
on its primary outcome, a composite cognitive score. 
Nevertheless, secondary and exploratory analyses revealed 
a nominal improvement in the modified motor score 
(mMS), especially in a subgroup of more severely affected 
participants. This subscore of the Unified Huntington’s 
Disease Rating Scale (UHDRS) total motor score (TMS) 
comprises items related with voluntary motor control (i.e., 
items 4–10 and 13–15) (19).
Building up on these results, two follow-up randomized 
controlled studies ensued: the MermaiHD study in 
32 European centres and the HART study in 27 North 
American centres. Based on the assumption that pridopidine 
could have an effect on voluntary movement control, both 
were designed and powered to show a difference in the 
mMS and recruited people with manifest HD and a mMS 
of 10 or more.
The MermaiHD study recruited 437 participants to 
investigate 45 and 90 mg of pridopidine daily compared 
with placebo over 26 weeks. Alas, this trial did not show an 
effect for its primary and secondary outcomes. Nonetheless, 
the analyses were statistically significant for the comparison 
90 mg versus placebo in the per-protocol sample (i.e., 70% 
or greater compliance with treatment and completed the 
study) for the mMS and in the intention-to-treat sample for 
the UHDRS TMS (20).
The HART study had a similar design and tested 
3 dosages of pridopidine (20, 45 or 90 mg daily) against 
placebo in 227 participants. The primary outcome evaluated 
at 12 weeks depicted no differences between the different 
dosages and the placebo arm, however secondary analyses 
showed a significant difference for UHDRS TMS for the 
comparison 90 mg versus placebo (22).
Lastly, the PRIDE-HD study recruited 408 participants 
with manifest HD, at least 25 points on the UHDRS TMS 
and 90% or less in the UHDRS independence score (IS), 
from 53 sites across 12 countries in Europe, North America 
and Australia. Follow-up was 53 weeks, and four doses of 
pridopidine (45, 67.5, 90 and 112.5 mg daily) were tested 
against placebo. The primary outcome was changed in 
the UHDRS TMS at 26 weeks and failed to be achieved. 
Exploratory analyses for all tested dosages showed similar 
results at 52 weeks. Exploratory analyses revealed an effect 
on the UHDRS total functional capacity (TFC) in the 45 mg 
arm. Subgroup post-hoc tests found this effect to be more 
evident in participants in earlier disease stages (24).
To summarise, the clinical development pipeline of 
pridopidine began with a negative, relatively small and 
short-lasting trial aimed at cognition but with interesting 
findings on a voluntary movements’ secondary outcome. It 
was followed by two well-powered but also negative trials 
designed to investigate the effects on voluntary movements. 
Both showed differences in a semi-structured neurological 
exam scale at the highest tested dosage (90 mg daily). A 
forth well-powered trial was deployed to investigate the 
effects on motor signs across a range of dosages. The 
trial was also negative, and none of the dosages shaped 
compelling differences after 6 months and 1 year on motor 
signs, but exploratory investigations disclosed an effect 
on functional capacity with low-dose pridopidine in early 
disease.
The cumulative evidence from these four trials seems 
to support that pridopidine is relatively safe and well-
tolerated. The a priori hypothesis that it has an effect on 
the cognitive features of HD has been proven false. The 
findings on motor effects learnt from the earliest trials 
were not replicated in a large built-for-purpose trial. Were 
the first ones spurious positive results stemming from 
exploratory analyses, or were the results of the latter trials 
just unfortunate? The investigators blame an unexpectedly 
high response by the placebo group in the primary 
Figure 1 Pridopidine molecule. 
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outcome. Indeed by the end of the study period, this was 
the arm with the largest effect size. The sponsor, Teva 
Pharmaceutical Industries Ltd., focused their attention on 
exploratory and post-hoc subgroup analyses concluding that 
“pridopidine demonstrates slowing of progression of Huntington 
disease in PRIDE-HD study as measured by Total Functional 
Capacity”. After sparked criticism from the clinical and 
scientific community, aware of the potential damages caused 
by such interpretations, the European Huntington’s Disease 
Network toned down the sponsor’s statement explaining 
that “this should not be misunderstood as a demonstration of 
disease modification or of neuroprotection”.
While there are multiple possible justifications for these 
results, one should always consider the possibility that 
pridopidine, as any other compound in development, may not 
induce the hypothesised clinical effect. The central nervous 
system therapeutic area has a low success rate from first-in-
man to registration of around 7–8% comparing with the 
grand mean of 11%, and other therapeutic areas such as 
cardiovascular where the success rate is around 20% (25). 
In neurology, the drug development pipeline performs 
appreciably poorly in the phase III and registration phases (25). 
In HD only 2 molecules survived these phases, and overall 
the success rate is even lower than that of other therapeutic 
areas (5). Many reasons have been hypothesized to explain 
such phenomenon: incomplete understanding of the disease 
physiopathology; weak association between the therapeutic 
target, and the disease pathogenesis and natural history; 
limited animal models; incomplete evaluation of preclinical 
effects; suboptimal pharmacokinetic and pharmacodynamic 
characteristics; limitations of current study designs 
(no biomarkers, short study durations); unenthusiastic 
commercial interests, among others. 
Pridopidine is an example where several of these factors 
came into play, halving the already low chances of first-in-
man to registration success. It is well stablished that only 
a small proportion of science generates positive results, 
including rigorous and well-report clinical trials (26). 
While the scientific milieu should reward progress, industry 
and researchers are often motivated by other factors. As 
tempting as it may sound to regard these after-the-event 
announcements relevant, history has thought us that 
hypotheses and new trials generated by post-hoc positive 
results are legitimate but may be wrong.
Understandably and in the absence of better approaches, 
this strategy is frequently used across medicine. Pridopidine 
seems unlikely to be clinically helpful for people with HD 
but we hope this story will teach us about the design of drug 
development programmes and what to avoid in the future 
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